The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton’s Tyrosine Kinase Inhibitor in Early Clinical Development
Open accessAbstract
Bruton's tyrosine kinase (Btk) is a nonreceptor cytoplasmic tyrosine kinase involved in B-cell and myeloid cell activation, downstream of B-cell and Fcγ receptors, respectively. Preclinical studies have indicated that inhibition of Btk activity might offer a potential therapy in autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus. Here we disclose the discovery and preclinical characterization of a potent, selective, and noncovalent Btk inhibitor currently in clinical development. GDC-0853 (29) suppresses B cell- and myeloid cell-mediated components of disease and demonstrates dose-dependent activity in an in vivo rat model of inflammatory arthritis. It demonstrates highly favorable safety, pharmacokinetic (PK), and pharmacodynamic (PD) profiles in preclinical and Phase 2 studies ongoing in patients with rheumatoid arthritis, lupus, and chronic spontaneous urticaria. On the basis of its potency, selectivity, long target residence time, and noncovalent mode of inhibition, 29 has the potential to be a best-in-class Btk inhibitor for a wide range of immunological indications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ames, B. N., McCann, J., & Yamasaki, E. (1975) · Mutation Research/Environmental Mutagenesis and Related Subjects · doi:10.1016/0165-1161(75)90046-1 · Cited by 7,381
The influence of drug-like concepts on decision-making in medicinal chemistry
Leeson, P. D., & Springthorpe, B. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2445 · Cited by 2,403
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
Byrd, J. C., Furman, R. R., Coutre, S. E., Flinn, I. W., Burger, J. A., Blum, K. A., Grant, B., Sharman, J. P., Coleman, M., Wierda, W. G., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215637 · Cited by 2,270
Self-citationTargeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma
Wang, M. L., Rule, S., Martin, P., Goy, A., Auer, R., Kahl, B. S., Jurczak, W., Advani, R. H., Romaguera, J. E., Williams, M. E., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1306220 · Cited by 1,685
Honigberg, L. A., Smith, A. M., Sirisawad, M., Verner, E., Loury, D., Chang, B., Li, S., Pan, Z., Thamm, D. H., Miller, R. A., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1004594107 · Cited by 1,561
BRUTON, O. C. (1952) · Pediatrics · doi:10.1542/peds.9.6.722 · Cited by 1,492
Drug-target residence time and its implications for lead optimization
Copeland, R. A., Pompliano, D. L., & Meek, T. D. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2082 · Cited by 1,464
Advani, R. H., Buggy, J. J., Sharman, J. P., Smith, S. M., Boyd, T. E., Grant, B., Kolibaba, K. S., Furman, R. R., Rodriguez, S., Chang, B. Y., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.7906 · Cited by 1,128
Ibrutinib in Previously Treated Waldenström’s Macroglobulinemia
Treon, S. P., Tripsas, C. K., Meid, K., Warren, D., Varma, G., Green, R., Argyropoulos, K. V., Yang, G., Cao, Y., Xu, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501548 · Cited by 942
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia
Byrd, J. C., Harrington, B., O’Brien, S., Jones, J. A., Schuh, A., Devereux, S., Chaves, J., Wierda, W. G., Awan, F. T., Brown, J. R., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1509981 · Cited by 897
Self-citationMutation of Unique Region of Bruton's Tyrosine Kinase in Immunodeficient XID Mice
Rawlings, D. J., Saffran, D. C., Tsukada, S., Largaespada, D. A., Grimaldi, J. C., Cohen, L., Mohr, R. N., Bazan, J. F., Howard, M., Copeland, N. G., et al. (1993) · Science · doi:10.1126/science.8332901 · Cited by 856
The Behavior and Significance of Slow‐Binding Enzyme Inhibitors
Morrison, J. F., & Walsh, C. T. (1988) · Advances in Enzymology - and Related Areas of Molecular Biology · doi:10.1002/9780470123072.ch5 · Cited by 840
The drug–target residence time model: a 10-year retrospective
Copeland, R. A. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.18 · Cited by 722
Discovery of Selective Irreversible Inhibitors for Bruton’s Tyrosine Kinase
Pan, Z., Scheerens, H., Li, S., Schultz, B. E., Sprengeler, P. A., Burrill, L. C., Mendonca, R. V., Sweeney, M. D., Scott, K. C. K., Grothaus, P. G., et al. (2007) · ChemMedChem · doi:10.1002/cmdc.200600221 · Cited by 674
Developing Irreversible Inhibitors of the Protein Kinase Cysteinome
Liu, Q., Sabnis, Y., Zhao, Z., Zhang, T., Buhrlage, S. J., Jones, L. H., & Gray, N. S. (2013) · Chemistry & Biology · doi:10.1016/j.chembiol.2012.12.006 · Cited by 652
Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis
Di Paolo, J. A., Huang, T., Balazs, M., Barbosa, J., Barck, K. H., Bravo, B. J., Carano, R. A. D., Darrow, J., Davies, D. R., DeForge, L. E., et al. (2011) · Nature Chemical Biology · doi:10.1038/nchembio.481 · Cited by 340
Self-citationTargeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma
Noy, A., de Vos, S., Thieblemont, C., Martin, P., Flowers, C. R., Morschhauser, F., Collins, G. P., Ma, S., Coleman, M., Peles, S., et al. (2017) · Blood · doi:10.1182/blood-2016-10-747345 · Cited by 298
Walter, H. S., Rule, S. A., Dyer, M. J. S., Karlin, L., Jones, C., Cazin, B., Quittet, P., Shah, N., Hutchinson, C. V., Honda, H., et al. (2016) · Blood · doi:10.1182/blood-2015-08-664086 · Cited by 268
X-Linked Agammaglobulinemia A Clinical and Molecular Analysis
Ochs, H. D., & Edvard Smith, C. I. (1996) · Medicine · doi:10.1097/00005792-199611000-00001 · Cited by 266
The role of Bruton's tyrosine kinase in B-cell development and function: a genetic perspective
Satterthwaite1, A. B., & Witte1, 2. (2000) · Immunological Reviews · doi:10.1034/j.1600-065x.2000.017504.x · Cited by 238
Evans, E. K., Tester, R., Aslanian, S., Karp, R., Sheets, M., Labenski, M. T., Witowski, S. R., Lounsbury, H., Chaturvedi, P., Mazdiyasni, H., et al. (2013) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.113.203489 · Cited by 220
PI3K signalling in B- and T-lymphocytes: new developments and therapeutic advances
So, L., & Fruman, D. A. (2012) · Biochemical Journal · doi:10.1042/bj20112092 · Cited by 218
Application of a J-Q Model for Fracture in the Ductile-Brittle Transition
Landes, J. (1997) · Fatigue and Fracture Mechanics: 27th Volume · doi:10.1520/stp16226s · Cited by 197
Bender, A. T., Gardberg, A., Pereira, A., Johnson, T., Wu, Y., Grenningloh, R., Head, J., Morandi, F., Haselmayer, P., & Liu-Bujalski, L. (2017) · Molecular Pharmacology · doi:10.1124/mol.116.107037 · Cited by 193
Btk function in B cell development and response
Satterthwaite, A. B., Li, Z., & Witte, O. N. (1998) · Seminars in Immunology · doi:10.1006/smim.1998.0123 · Cited by 184
Fragment screening: an introduction
Leach, A. R., Hann, M. M., Burrows, J. N., & Griffen, E. J. (2006) · Molecular BioSystems · doi:10.1039/b610069b · Cited by 163
Regulation of B Lymphocyte Development and Activation by Bruton's Tyrosine Kinase
Khan, W. N. (2001) · Immunologic Research · doi:10.1385/ir:23:2-3:147 · Cited by 156
Watterson, S. H., Lucca, G. V. D., Shi, Q., Langevine, C. M., Liu, Q., Batt, D. G., Bertrand, M. B., Gong, H., Dai, J., Yip, S. H., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01088 · Cited by 155
Xu, D., Kim, Y. D., Postelnek, J., Vu, M. D., Hu, D., Liao, C., Bradshaw, M., Hsu, J., Zhang, J., Pashine, A., et al. (2012) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.111.187740 · Cited by 149
Battling Btk mutants with noncovalent inhibitors that overcome Cys481 and Thr474 mutations
Johnson, A. R., Kohli, P. B., Katewa, A., Gogol, E., Belmont, L. D., Choy, R., Penuel, E., Burton, L., Eigenbrot, C., Yu, C., et al. (2016) · ACS Chemical Biology · doi:10.1021/acschembio.6b00480 · Cited by 137
Self-citationLou, Y. C., Han, X., Kuglstatter, A., Kondru, R. K., Sweeney, Z. K., Soth, M., McIntosh, J. E., Litman, R., Suh, J. M., Koçer, B., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500305p · Cited by 114
Selective inhibition of BTK prevents murine lupus and antibody-mediated glomerulonephritis
Rankin, A. L., Seth, N., Keegan, S., Andreyeva, T., Cook, T. A., Edmonds, J., Mathialagan, N., Benson, M. J., Syed, J., Zhan, Y., et al. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1301553 · Cited by 113
Expression of Bruton's tyrosine kinase protein within the B cell lineage
Genevier, H. C., Hinshelwood, S., Gaspar, H. B., Rigley, K. P., Brown, D. T., Saeland, S., Rousset, F., Levinsky, R. J., Callard, R. E., Kinnon, C., et al. (1994) · European Journal of Immunology · doi:10.1002/eji.1830241228 · Cited by 106
Bruton's Tyrosine Kinase is involved in innate and adaptive immunity.
Brunner, C., Müller, B., & Wirth, T. C. (2005) · PubMed · doi:10.14670/hh-20.945 · Cited by 106
Hutcheson, J., Vanarsa, K., Bashmakov, A., Grewal, S., Sajitharan, D., Chang, B. Y., Buggy, J. J., Zhou, X. J., Du, Y., Satterthwaite, A. B., et al. (2012) · Arthritis Research & Therapy · doi:10.1186/ar4086 · Cited by 102
The Role of Tec Family Kinases in Myeloid Cells
Schmidt, U., Boucheron, N., Unger, B., & Ellmeier, W. (2004) · International Archives of Allergy and Immunology · doi:10.1159/000078339 · Cited by 92
Lou, Y. C., Owens, T. D., Kuglstatter, A., Kondru, R. K., & GOLDSTEIN, D. M. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm300035p · Cited by 91
Liu, L., Paolo, J. A. D., Barbosa, J., Rong, H., Reif, K., & Wong, H. H. (2011) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.111.181545 · Cited by 89
Self-citationRobak, T., & Robak, E. (2012) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2012.685650 · Cited by 88
Mina‐Osorio, P., LaStant, J., Keirstead, N. D., Whittard, T., Ayala, J., Stefanova, S., Garrido, R., Dimaano, N. M., Hilton, H., Giron, M., et al. (2013) · Arthritis & Rheumatism · doi:10.1002/art.38047 · Cited by 84
Puri, K. D., Paolo, J. A. D., & Gold, M. R. (2013) · International Reviews of Immunology · doi:10.3109/08830185.2013.818140 · Cited by 78
Pai, R., French, D. M., Ma, N., Hötzel, K., Plise, E. G., Salphati, L., Setchell, K. D. R., Ware, J. A., Lauriault, V., Schutt, L., et al. (2012) · Toxicological Sciences · doi:10.1093/toxsci/kfs011 · Cited by 78
Self-citationFragment-Based Discovery of a Small Molecule Inhibitor of Bruton’s Tyrosine Kinase
Smith, C. R., Dougan, D. R., Komandla, M., Kanouni, T., Knight, B., Lawson, J. D., Sabat, M. P., Taylor, E. R., Vu, P. H., & Wyrick, C. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00734 · Cited by 75
Katewa, A., Wang, Y., Hackney, J. A., Huang, T., Suto, E., Ramamoorthi, N., Austin, C. D., Bremer, M. C. D., Chen, J. Z., Crawford, J. J., et al. (2017) · JCI Insight · doi:10.1172/jci.insight.90111 · Cited by 73
Self-citationPotent and selective Bruton’s tyrosine kinase inhibitors: Discovery of GDC-0834
Young, W. B., Barbosa, J., Blomgren, P., Bremer, M. C. D., Crawford, J. J., Dambach, D. M., Gallion, S., Hymowitz, S. G., Kropf, J. E., Lee, S., et al. (2015) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2015.01.032 · Cited by 70
Self-citationBtk inhibition treats TLR7/IFN driven murine lupus
Bender, A. T., Pereira, A., Fu, K., Samy, E. T., Wu, Y., Liu‐Bujalski, L., Caldwell, R. D., Chen, Y.-Y., Tian, H., Morandi, F., et al. (2016) · Clinical Immunology · doi:10.1016/j.clim.2016.01.012 · Cited by 52
Young, W. B., Barbosa, J., Blomgren, P., Bremer, M. C. D., Crawford, J. J., Dambach, D. M., Eigenbrot, C. W., Gallion, S., Johnson, A. R., Kropf, J. E., et al. (2015) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2015.11.076 · Cited by 43
Self-citationLee, S. K., Xing, J. W., Catlett, I. M., Adamczyk, R., Griffies, A., Liu, A., Murthy, B., & Nowak, M. (2017) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-017-2226-2 · Cited by 41
Chalmers, S. A., Doerner, J., Bosanac, T., Khalil, S. D. S., Smith, D. M., Harcken, C., Dimock, J., Der, E. B., Herlitz, L., Webb, D., et al. (2016) · Scientific Reports · doi:10.1038/srep26164 · Cited by 40
Wang, X., Barbosa, J., Blomgren, P., Bremer, M. C. D., Chen, J., Crawford, J. J., Deng, W., Dong, L., Eigenbrot, C. W., Gallion, S., et al. (2017) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.7b00103 · Cited by 38
Self-citationChang, B. Y., Furman, R. R., Zapatka, M., Barrientos, J. C., Li, D., Steggerda, S. M., Eckert, K., Francesco, M. R., Woyach, J. A., Johnson, A. J., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.15_suppl.7014 · Cited by 36
Self-citationBruton’s Tyrosine Kinase Small Molecule Inhibitors Induce a Distinct Pancreatic Toxicity in Rats
Erickson, R. I., Schutt, L., Tarrant, J. M., McDowell, M., Liu, L., Johnson, A. R., Lewin-Koh, S.-C., Hedehus, M., Ross, J., Carano, R. A. D., et al. (2016) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.116.236224 · Cited by 24
Self-citationFeng, J. A., Aliagas, I., Bergeron, P., Blaney, J., Bradley, E. K., Koehler, M. F. T., Lee, M., Ortwine, D. F., Tsui, V., Wu, J. C., et al. (2015) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-015-9845-4 · Cited by 20
Self-citationPyrrolo[2,3-d]pyrimidines active as Btk inhibitors
Musumeci, F., Sanna, M., Greco, C., Giacchello, I., Fallacara, A. L., Amato, R., & Schenone, S. (2017) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2017.1355908 · Cited by 15
Cited by
Put a ring on it: application of small aliphatic rings in medicinal chemistry
Bauer, M. R., Di Fruscia, P., Lucas, S. C. C., Michaelides, I. N., Nelson, J. E., Storer, R. I., & Whitehurst, B. C. (2021) · RSC Medicinal Chemistry · doi:10.1039/d0md00370k · Cited by 479
Challenges and Opportunities in Cancer Drug Resistance
Ward, R. A., Fawell, S., Floc’h, N., Flemington, V., McKerrecher, D., & Smith, P. D. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.0c00383 · Cited by 445
Buhimschi, A. D., Armstrong, H. A., Toure, M., Jaime-Figueroa, S., Chen, T. L., Lehman, A. M., Woyach, J. A., Johnson, A. J., Byrd, J. C., & Crews, C. M. (2018) · Biochemistry · doi:10.1021/acs.biochem.8b00391 · Cited by 394
Self-citationPlacebo-controlled trial of an oral BTK inhibitor in multiple sclerosis
Montalban, X., Arnold, D. L., Weber, M. S., Staikov, I., Piasecka-Stryczynska, K., Willmer, J., Martin, E. C., Dangond, F., Syed, S., & Wolinsky, J. S. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1901981 · Cited by 324
Comparative Analysis of BTK Inhibitors and Mechanisms Underlying Adverse Effects
Estupiñán, H. Y., Berglöf, A., Zain, R., & Smith, C. I. E. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.630942 · Cited by 267
Metadata
- Authors
- Crawford, J. J., Johnson, A. R., Misner, D. L., Belmont, L. D., Castanedo, G., Choy, R., Coraggio, M., Dong, L., Eigenbrot, C., Erickson, R., Ghilardi, N., Hau, J., Katewa, A., Kohli, P. B., Lee, W., Lubach, J. W., McKenzie, B. S., Ortwine, D. F., Schutt, L., Tay, S., Wei, B., Reif, K., Liu, L., Wong, H., & Young, W. B.
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2018-02-19
- Volume
- 61
- Issue
- 6
- Pages
- 2227-2245
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W2788356134
- Cited by
- 257
- References
- 54
- FWCI
- 21.10
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.